Needham Maintains Buy on Cartesian Therapeutics, Lowers Price Target to $40

Benzinga · 05/08 18:57
Needham analyst Gil Blum maintains Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and lowers the price target from $41 to $40.